TY - JOUR
T1 - Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
AU - Molldrem, Jeffrey J.
AU - Lee, Peter P.
AU - Wang, Changqing
AU - Felio, Kyrie
AU - Kantarjian, Hagop M.
AU - Champlin, Richard E.
AU - Davis, Mark M.
N1 - Funding Information:
Acknowledgments We thank the HLA laboratory at the M. D. Anderson Cancer Center for performing HLA testing of all patients, donors and healthy volunteers. Supported by grants from the Leukemia Society of America (LSA 6148-99 to J.J.M.), the U.S. Public Health Service (CA81247 to J.J.M., AI22511 to M.M.D.), and the Howard Hughes Medical Institute (to M.M.D.). P. P. Lee is supported by a physician
PY - 2000/9
Y1 - 2000/9
N2 - Although the immune system has long been implicated in the control of cancer, evidence for specific and efficacious immune responses in human cancer has been lacking. In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-α2b (IFN-α2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. We previously demonstrated that PR1, a peptide derived from proteinase 3, is a potential target for CML-specific T cells. Here we studied 38 CML patients treated with allogeneic BMT, IFN-α2b or chemotherapy to look for PR1-specific T cells using PR1/HLA-A*0201 tetrameric complexes. There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT. This provides for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.
AB - Although the immune system has long been implicated in the control of cancer, evidence for specific and efficacious immune responses in human cancer has been lacking. In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-α2b (IFN-α2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. We previously demonstrated that PR1, a peptide derived from proteinase 3, is a potential target for CML-specific T cells. Here we studied 38 CML patients treated with allogeneic BMT, IFN-α2b or chemotherapy to look for PR1-specific T cells using PR1/HLA-A*0201 tetrameric complexes. There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT. This provides for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.
UR - http://www.scopus.com/inward/record.url?scp=0033826799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033826799&partnerID=8YFLogxK
U2 - 10.1038/79526
DO - 10.1038/79526
M3 - Article
C2 - 10973322
AN - SCOPUS:0033826799
SN - 1078-8956
VL - 6
SP - 1018
EP - 1023
JO - Nature medicine
JF - Nature medicine
IS - 9
ER -